Hazards of inadequate fluconazole dosage to treat deep-seated or systemic Candida albicans infection

Journal of Infection

Volumn 35, Issue 3, 1997, Pages 295-297

  Flanagan, P G ^a   Barnes, R A ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CASE REPORT; CLINICAL PROTOCOL; DOSE CALCULATION; ENDOCARDITIS; FEMALE; GOOD CLINICAL PRACTICE; HEMOFILTRATION; HOSPITAL PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYCOSIS; ORAL DRUG ADMINISTRATION; OSTEOMYELITIS; SUPERINFECTION; TREATMENT FAILURE;

EID: 0031454067     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(97)93270-9     Document Type: Article

References (23)

1. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Medicine 1994; 20: 522-528.
2. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidaemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-421.
3. Edwards JE. Invasive Candida infections. Evolution of a fungal pathogen. N Engl J Med 1991; 324: 1059-1062.
4. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-272.
5. Laine L, Dretler RH, Conteas C et al. Fluconazole compared with ketoconazole for the treatment of Candida oesophagitis in AIDS. Ann Intern Med 1992; 177: 655-660.
6. Rex J, Bennett JE, Sugar AM et al. A randomised trial comparing fluconazole with amphotericin B for the treatment of candidaemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-1330.
7. Johnson EM, Warnock DW. Azole resistance in yeasts. J Antimicrob Chemother 1995; 36: 751-755.
8. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35: 103-104.
9. Sangeorzan JA, Bradley SF, He X et al. Epidemiology of oral candidiasis in HIV-infected patients: colonisation, infection, treatment and emergence of fluconazole resistance. Am J Med 1994; 97: 339-346.
10. Ruhnke M, Eigler A, Tennagen I, Geisler B, Engelmann E, Trauttmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092-2098.
11. Goff D, Koletar S, Buesching W, Barnisham J, Fass RJ. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995; 20: 77-83.
12. Revankar SJ, Kirkpatrick WR, McAtee RK et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 174: 821-827.
13. Johnson EM, Richardson MD, Warnock DW. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother 1984; 13: 547-558.
14. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 6: 367-381.
15. Working party of British Society of Antimicrobial Chemotherapy. Antifungal drug susceptibility testing. J Antimicrob Chemother 1995; 36: 899-909.
16. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in-vitro data with clinical outcome, J Clin Microbiol 1996; 34: 489-495.
17. Rodriguez-Tudela JL, Martinez-Suarez JV, Dronda F, Laguna F, Chaves F, Valencia E. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother 1995; 35: 793-804.
18. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
19. Venditti M, De Bernardis F, Micozzi A. Fluconazole treatment of catheter-related right sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis 1992; 14: 422-426.
20. Edwards JE, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in non-neutropenic patients. Clin Infect Dis 1992; 14 (Suppl.): S106-113.
21. Sandford JP, Gilbert DN, Gerberding JL, Sande MA. Guide to antimicrobial therapy 1994; 107-111. Antimicrobial Therapy Inc, Dallas.
22. Scholz J, Schulz M, Steinfath M, Hover S, Bause H. Fluconazole is removed by continuous venovenous haemofiltration in a liver transplant patient. J Mol Med 1995; 73: 145-147.
23. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Effect of continuous arteriovenous haemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994; 14: 502-505.